{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:57:33Z","timestamp":1791302253853,"version":"4.1.0"},"reference-count":53,"publisher":"American Chemical Society (ACS)","issue":"39","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["25-24-00406"],"award-info":[{"award-number":["25-24-00406"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study provides the first assessment of the therapeutic potential of phosphoramide benzoazole oligonucleotides (PABAOs) bearing N-benzimidazole moieties. Two series of antisense oligonucleotides (ASOs) targeting distinct regions of enhanced green fluorescent protein (eGFP) mRNA were synthesized via automated solid-phase phosphoramidite chemistry. Three N-benzimidazole modification patterns for each ASO were systematically evaluated. Incorporation of modification pairs proximal to both the 3\u2032 and 5\u2032 termini conferred enhanced ASO\u2019s resistance to degradation in fetal bovine serum (FBS). Although N-benzimidazole incorporation reduced hybridization affinity, all modified ASOs retained the ability to form stable complexes with structured RNA targets under conditions close to physiological. Notably, one of the two series of modified ASOs preserved RNase H-mediated cleavage activity at levels comparable to its unmodified counterpart. Cytotoxicity assessments revealed sequence-specific effects, with modified ASOs demonstrating negligible toxicity in HEK293-eGFP cells at concentrations up to 10 \u03bcM. Among the constructs, the one ASO bearing paired N-benzimidazole modifications proximal to both the 3\u2032 and 5\u2032 termini induced substantial eGFP knockdown, whereas the other ASOs and controls, including scrambled and phosphorothioate-containing variants, were inactive. In addition, oligonucleotide accumulation in cells increases with the number of modifications in the ASOs. These results identify N-benzimidazole-modified PABAOs as RNase H-competent antisense oligomers with tunable nuclease resistance and support further optimization of benzoazole backbones for therapeutic ASO design.<\/jats:p>","DOI":"10.1021\/acsomega.6c08822","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:01:28Z","timestamp":1790384488000},"page":"60473-60484","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Potential\nof Phosphoramide\n                    <i>N<\/i>\n                    -Benzimidazole Oligonucleotides\n(PABAOs) as Antisense Agents"],"prefix":"10.1021","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3551-2458","authenticated-orcid":true,"given":"Svetlana V.","family":"Vasilyeva","sequence":"first","affiliation":[{"name":"Knorre Institute of Chemical Biology Fundamental Medicine, SB RAS , 8, Ac. Lavrentiev ave. , ,","place":["Novosibirsk, Russia, 630090"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.","family":"Pavlova","sequence":"additional","affiliation":[{"name":"Knorre Institute of Chemical Biology Fundamental Medicine, SB RAS , 8, Ac. Lavrentiev ave. , ,","place":["Novosibirsk, Russia, 630090"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina I.","family":"Novgorodtseva","sequence":"additional","affiliation":[{"name":"Knorre Institute of Chemical Biology Fundamental Medicine, SB RAS , 8, Ac. Lavrentiev ave. , ,","place":["Novosibirsk, Russia, 630090"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9730-3718","authenticated-orcid":true,"given":"Elizaveta E.","family":"Baranovskaya","sequence":"additional","affiliation":[{"name":"Knorre Institute of Chemical Biology Fundamental Medicine, SB RAS , 8, Ac. Lavrentiev ave. , ,","place":["Novosibirsk, Russia, 630090"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana A.","family":"Gulyaeva","sequence":"additional","affiliation":[{"name":"Knorre Institute of Chemical Biology Fundamental Medicine, SB RAS , 8, Ac. Lavrentiev ave. , ,","place":["Novosibirsk, Russia, 630090"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga A.","family":"Koval","sequence":"additional","affiliation":[{"name":"Knorre Institute of Chemical Biology Fundamental Medicine, SB RAS , 8, Ac. Lavrentiev ave. , ,","place":["Novosibirsk, Russia, 630090"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2295-6455","authenticated-orcid":true,"given":"Elena V.","family":"Dmitrienko","sequence":"additional","affiliation":[{"name":"Knorre Institute of Chemical Biology Fundamental Medicine, SB RAS , 8, Ac. Lavrentiev ave. , ,","place":["Novosibirsk, Russia, 630090"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3889-9464","authenticated-orcid":true,"given":"Alexander A.","family":"Lomzov","sequence":"additional","affiliation":[{"name":"Knorre Institute of Chemical Biology Fundamental Medicine, SB RAS , 8, Ac. Lavrentiev ave. , ,","place":["Novosibirsk, Russia, 630090"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"3","key":"2026100610464842900_cit1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The Chemical Evolution of Oligonucleotide Therapies\nof Clinical Utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"2026100610464842900_cit2","doi-asserted-by":"publisher","first-page":"1006304","DOI":"10.3389\/fphar.2022.1006304","article-title":"A Perspective on\nOligonucleotide Therapy: Approaches to Patient Customization","volume":"13","author":"Thakur","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"2026100610464842900_cit3","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Structure\nand Function of Approved Oligonucleotide\nTherapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"2026100610464842900_cit4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in Oligonucleotide Drug\nDelivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"1","key":"2026100610464842900_cit5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense Oligonucleotides:\nThe next Frontier for Treatment\nof Neurological Disorders","volume":"14","author":"Rinaldi","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"2026100610464842900_cit6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/ph19020244","article-title":"FDA TIDES\n(Peptides and Oligonucleotides) Harvest","volume":"19","author":"AlShaer","year":"2026","journal-title":"Pharmaceuticals"},{"key":"2026100610464842900_cit7","unstructured":"Antisense Oligonucleotides Market Report. https:\/\/www.futuremarketinsights.com\/reports\/antisense-oligonucleotides-market."},{"issue":"21","key":"2026100610464842900_cit8","doi-asserted-by":"publisher","first-page":"10524","DOI":"10.3390\/ijms262110524","article-title":"Application\nof Antisense Oligonucleotides as an Alternative Approach for Gene\nExpression Control and Functional Studies","volume":"26","author":"Szukowska","year":"2025","journal-title":"Int.\nJ. Mol. Sci."},{"issue":"7","key":"2026100610464842900_cit9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14304\/SURYA.JPR.V4N7.5","article-title":"RNA Therapeutics:\nRNAi and Antisense Mechanisms and Clinical Applications","volume":"4","author":"Chery","year":"2016","journal-title":"Postdoc J."},{"issue":"1","key":"2026100610464842900_cit10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0167-4781(99)00148-7","article-title":"Molecular\nMechanisms of Action of Antisense Drugs","volume":"1489","author":"Crooke","year":"1999","journal-title":"Biochim.\nBiophys. Acta, Gene Struct. Expression"},{"issue":"7","key":"2026100610464842900_cit11","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1021\/ar2002123","article-title":"The Chemistry\nand Biology of Oligonucleotide\nConjugates","volume":"45","author":"Juliano","year":"2012","journal-title":"Acc. Chem. Res"},{"issue":"18","key":"2026100610464842900_cit12","doi-asserted-by":"publisher","first-page":"8955","DOI":"10.1093\/nar\/gkv920","article-title":"The Rates of the Major Steps in the Molecular Mechanism\nof RNase H1-Dependent Antisense Oligonucleotide Induced Degradation\nof RNA","volume":"43","author":"Vickers","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"(24)","key":"2026100610464842900_cit13","doi-asserted-by":"publisher","first-page":"11535","DOI":"10.1073\/PNAS.88.24.11535","article-title":"How Does\nRNase H Recognize a DNA.RNA Hybrid?","volume":"88","author":"Nakamura","year":"1991","journal-title":"Proc. Natl.\nAcad. Sci. U. S. A."},{"issue":"3","key":"2026100610464842900_cit14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular\nUptake and Trafficking of Antisense Oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"2026100610464842900_cit15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101752","article-title":"Defining\nthe Factors That Contribute to On-Target Specificity of Antisense\nOligonucleotides","volume":"9","author":"Lima","year":"2014","journal-title":"PLoS One"},{"key":"2026100610464842900_cit16","doi-asserted-by":"publisher","first-page":"107595","DOI":"10.1016\/j.bioorg.2024.107595","article-title":"RNase H-Sensitive Multifunctional\nASO-Based Constructs as Promising Tools for the Treatment of Multifactorial\nComplex Pathologies","volume":"150","author":"Mata-Ventosa","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"1","key":"2026100610464842900_cit17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0167-4781(99)00143-8","article-title":"Two Problems\nin Antisense Biotechnology: In Vitro Delivery and the Design of Antisense\nExperiments","volume":"1489","author":"Stein","year":"1999","journal-title":"Biochim. Biophys. Acta, Gene Struct.\nExpression"},{"issue":"5","key":"2026100610464842900_cit18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1089\/oli.1.1997.7.473","article-title":"Evaluation\nof the Toxicity of ISIS 2302, a Phosphorothioate Oligonucleotide,\nin a 4-Week Study in CD-1 Mice","volume":"7","author":"Henry","year":"1997","journal-title":"Antisense Nucleic\nAcid Drug Dev."},{"issue":"1","key":"2026100610464842900_cit19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/019262339902700117","article-title":"Correlation\nof Toxicity and Pharmacokinetic Properties of a Phosphorothioate Oligonucleotide\nDesigned to Inhibit ICAM-1","volume":"27","author":"Henry","year":"1999","journal-title":"Toxicol. Pathol."},{"issue":"2","key":"2026100610464842900_cit20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0300-483X(97)03661-5","article-title":"Evaluation\nof the Toxicity of ISIS 2302, a Phosphorothioate Oligonucleotide,\nin a Four-Week Study in Cynomolgus Monkeys","volume":"120","author":"Henry","year":"1997","journal-title":"Toxicology"},{"issue":"19","key":"2026100610464842900_cit21","doi-asserted-by":"publisher","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","article-title":"Evaluation\nof 2\u2018-Modified Oligonucleotides Containing 2\u2018-Deoxy\nGaps as Antisense Inhibitors of Gene Expression","volume":"268","author":"Monia","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"6","key":"2026100610464842900_cit22","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1073\/pnas.94.6.2620","article-title":"Mixed-Backbone\nOligonucleotides as Second Generation Antisense Oligonucleotides:\nIn Vitro and in Vivo Studies","volume":"94","author":"Agrawal","year":"1997","journal-title":"Proc. Natl. Acad.\nSci. U. S. A."},{"issue":"1","key":"2026100610464842900_cit23","doi-asserted-by":"publisher","first-page":"113442","DOI":"10.1016\/j.yexcr.2022.113442","article-title":"Locked Nucleic Acid (LNA): A Modern Approach to Cancer\nDiagnosis and Treatment","volume":"423","author":"Kamali","year":"2023","journal-title":"Exp. Cell Res."},{"issue":"4","key":"2026100610464842900_cit24","first-page":"583","article-title":"Therapeutic\nPeptide Nucleic Acids: Principles, Limitations, and Opportunities","volume":"90","author":"Quijano","year":"2017","journal-title":"Yale J. Biol. Med."},{"issue":"14","key":"2026100610464842900_cit25","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1021\/bi0122112","article-title":"Novel Antisense and Peptide Nucleic Acid Strategies\nfor Controlling Gene Expression","volume":"41","author":"Braasch","year":"2002","journal-title":"Biochemistry"},{"issue":"23","key":"2026100610464842900_cit26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.32607\/20758251-2014-6-4-116-118","article-title":"Phosphoryl\nGuanidines: A New Type\nof Nucleic Acid Analogues","volume":"6","author":"Kupryushkin","year":"2014","journal-title":"Acta Nat."},{"key":"2026100610464842900_cit27","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.omtn.2022.04.007","article-title":"Preclinical Evaluation\nof WVE-004, Aninvestigational Stereopure Oligonucleotide Forthe Treatment\nof C9orf72-Associated ALS or FTD","volume":"28","author":"Liu","year":"2022","journal-title":"Mol. Ther\nNucleic Acids"},{"issue":"16","key":"2026100610464842900_cit28","doi-asserted-by":"publisher","first-page":"9026","DOI":"10.1093\/NAR\/GKAB718","article-title":"Towards Next Generation\nAntisense Oligonucleotides: mesylphosphoramidate Modification Improves\nTherapeutic Index And Duration Of Effect Of Gapmer Antisense Oligonucleotides","volume":"49","author":"Anderson","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"2026100610464842900_cit29","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1021\/acsomega.2c07083","article-title":"Synthesis\nof Oligonucleotides Carrying Inter-Nucleotide N -(Benzoazole)-Phosphoramide\nMoieties","volume":"8","author":"Vasilyeva","year":"2023","journal-title":"ACS Omega"},{"key":"2026100610464842900_cit30","doi-asserted-by":"publisher","first-page":"149390","DOI":"10.1016\/j.bbrc.2023.149390","article-title":"Properties of Phosphoramide Benzoazole\nOligonucleotides\n(PABAOs). I. Structure and Hybridization Efficiency of N-Benzimidazole\nDerivatives","volume":"693","author":"Golyshev","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2026100610464842900_cit31","doi-asserted-by":"publisher","first-page":"150997","DOI":"10.1016\/j.bbrc.2024.150997","article-title":"Properties of Phosphoramide\nBenzoazole Oligonucleotides (PABAOs). II. Structure and Hybridization\nEfficiency of N-Benzoxazole Derivatives","volume":"740","author":"Yushin","year":"2024","journal-title":"Biochem.\nBiophys. Res. Commun."},{"key":"2026100610464842900_cit32","doi-asserted-by":"publisher","first-page":"153170","DOI":"10.1016\/J.BBRC.2025.153170","article-title":"Properties of\nPhosphoramide Benzoazole Oligonucleotides (PABAOs). III. Structure\nand Hybridization Efficiency of N-Benzothiazole Derivatives","volume":"796","author":"Yushin","year":"2026","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"2026100610464842900_cit33","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0006-291X(02)02013-2","article-title":"Comparison of Antisense\nOligonucleotides and SiRNAs in Cell Culture\nand in Vivo","volume":"296","author":"Bertrand","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2026100610464842900_cit34","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.omtn.2020.01.018","article-title":"Efficient\nDelivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles\nIn Vitro and In Vivo","volume":"19","author":"Yang","year":"2020","journal-title":"Mol. Ther Nucleic Acids"},{"issue":"10","key":"2026100610464842900_cit35","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1093\/nar\/gkac037","article-title":"Impact of Guanidine-Containing\nBackbone Linkages on Stereopure Antisense Oligonucleotides in the\nCNS","volume":"50","author":"Kandasamy","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"2026100610464842900_cit36","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41587-022-01225-1","article-title":"Endogenous ADAR-Mediated RNA Editing in Non-Human Primates\nUsing Stereopure Chemically Modified Oligonucleotides","volume":"40","author":"Monian","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"2026100610464842900_cit37","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.bbrc.2019.04.024","article-title":"Diastereomers of a Mono-Substituted\nPhosphoryl Guanidine Trideoxyribonucleotide: Isolation and Properties","volume":"513","author":"Lomzov","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"2026100610464842900_cit38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1134\/S0006350912010137","article-title":"Considering the\nOligonucleotide Secondary Structures\nin Thermodynamic and Kinetic Analysis of DNA Duplex Formation","volume":"57","author":"Lomzov","year":"2012","journal-title":"Biophysics"},{"issue":"4","key":"2026100610464842900_cit39","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0006-291X(02)02013-2","article-title":"Comparison of Antisense Oligonucleotides\nand SiRNAs in Cell Culture\nand in Vivo","volume":"296","author":"Bertrand","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"2026100610464842900_cit40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1089\/nat.2019.0806","article-title":"Phosphorothioate\nAntisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body\nAssembly","volume":"29","author":"Wang","year":"2019","journal-title":"Nucleic Acid Ther."},{"issue":"3","key":"2026100610464842900_cit41","doi-asserted-by":"publisher","first-page":"gkaf1333","DOI":"10.1093\/nar\/gkaf1333","article-title":"Acute Neuronal Inhibition Response Caused by\nPhosphorothioate Antisense Oligonucleotides Following Local Delivery\nto the Central Nervous System","volume":"54","author":"O\u2019rourke","year":"2026","journal-title":"Nucleic Acids\nRes."},{"issue":"22","key":"2026100610464842900_cit42","doi-asserted-by":"publisher","first-page":"6585","DOI":"10.1093\/nar\/gkh997","article-title":"Sequence-Dependent Cytotoxicity of\nSecond-Generation Oligonucleotides","volume":"32","author":"Drygin","year":"2004","journal-title":"Nucleic\nAcids Res."},{"key":"2026100610464842900_cit43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.omtn.2021.11.025","article-title":"Antisense Oligonucleotide Gapmers\nContaining Phosphoryl Guanidine Groups Reverse MDR1-Mediated Multiple\nDrug Resistance of Tumor Cells","volume":"27","author":"Kupryushkin","year":"2022","journal-title":"Mol. Ther Nucleic\nAcids"},{"issue":"51","key":"2026100610464842900_cit44","doi-asserted-by":"publisher","first-page":"32370","DOI":"10.1073\/pnas.2016158117","article-title":"Mesyl Phosphoramidate Backbone Modified Antisense\nOligonucleotides Targeting MiR-21 with Enhanced in Vivo Therapeutic\nPotency","volume":"117","author":"Patutina","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026100610464842900_cit45","doi-asserted-by":"publisher","first-page":"108313","DOI":"10.1016\/j.bioorg.2025.108313","article-title":"Synthesis\nand Physicochemical Properties of New Phosphoramide Oligodeoxyribonucleotides.\nI. N-Caffeine Derivatives","volume":"157","author":"Novgorodtseva","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"18","key":"2026100610464842900_cit46","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.1093\/nar\/gkg733","article-title":"Cationic Phosphoramidate\n-Oligonucleotides Efficiently Target Single-Stranded DNA and RNA and\nInhibit Hepatitis C Virus IRES-Mediated Translation","volume":"31","author":"Michel","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"2026100610464842900_cit47","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.omtn.2022.05.024","article-title":"RNA Modifications\nCan Affect RNase H1-Mediated PS-ASO Activity","volume":"28","author":"Doxtader Lacy","year":"2022","journal-title":"Mol. Ther Nucleic Acids"},{"issue":"2","key":"2026100610464842900_cit48","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense Oligonucleotides\nContaining Locked Nucleic Acid Improve Potency but Cause Significant\nHepatotoxicity in Animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res."},{"issue":"22","key":"2026100610464842900_cit49","doi-asserted-by":"publisher","first-page":"12932","DOI":"10.1093\/nar\/gkx1073","article-title":"RNase H Sequence Preferences\nInfluence Antisense Oligonucleotide Efficiency","volume":"45","author":"Kie\u0142pin\u0301ski","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"2026100610464842900_cit50","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1089\/scd.2005.14.487","article-title":"Stable Plasmid-Based SiRNA Silencing of Gene Expression\nin Human Embryonic Stem Cells","volume":"14","author":"Liu","year":"2005","journal-title":"Stem Cells Dev."},{"key":"2026100610464842900_cit51","first-page":"411","article-title":"RNA Hydrolysis Catalyzed by Imidazole\nas a Reaction for Studying the Secondary Structure of RNA and Complexes\nof RNA with Oligonucleotides","volume":"349","author":"Vlasov","year":"1996","journal-title":"Dokl. Akad. Nauk."},{"issue":"8","key":"2026100610464842900_cit52","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1093\/nar\/4.8.2527","article-title":"Mapping Adenines,\nGuanines, and Pyrimidines\nin RNA","volume":"4","author":"Donis-Keller","year":"1977","journal-title":"Nucleic Acids Res."},{"key":"2026100610464842900_cit53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1471-2199-9-60","article-title":"Off-Target\nEffects of SiRNA Specific for GFP","volume":"9","author":"Tschuch","year":"2008","journal-title":"BMC Mol.\nBiol."}],"container-title":["ACS Omega"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsomega.6c08822","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/11\/39\/60473\/68664374\/acsomega.6c08822.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/11\/39\/60473\/68664374\/acsomega.6c08822.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:23:58Z","timestamp":1791300238000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/acsodf\/article\/11\/39\/60473\/5439210\/Exploring-the-Potential-of-Phosphoramide-N"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":53,"journal-issue":{"issue":"39","published-online":{"date-parts":[[2026,9,25]]},"published-print":{"date-parts":[[2026,10,6]]}},"URL":"https:\/\/doi.org\/10.1021\/acsomega.6c08822","relation":{},"ISSN":["2470-1343"],"issn-type":[{"value":"2470-1343","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}